Journal Mobile Options
Table of Contents
Vol. 90, No. 2, 2006
Issue release date: August 2006
Biol Neonate 2006;90:135–144

BAY 41-2272, a Direct Activator of Soluble Guanylate Cyclase, Reduces Right Ventricular Hypertrophy and Prevents Pulmonary Vascular Remodeling during Chronic Hypoxia in Neonatal Rats

Deruelle P. · Balasubramaniam V. · Kunig A.M. · Seedorf G.J. · Markham N.E. · Abman S.H.
aDepartment of Pediatrics, Pediatric Heart Lung Center, University of Colorado School of Medicine, Denver, Colo., USA; bFaculté de Médecine, Université de Lille II, Lille, France

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Exposure to hypoxia during the first weeks of life in newborn rats decreases vascular growth and alveolarization and causes pulmonary hypertension (PH). BAY 41-2272 is a novel direct activator of soluble guanylate cyclase independent of nitric oxide, effective as an acute pulmonary vasodilator in an animal model of persistent pulmonary hypertension of the newborn, but whether prolonged BAY 41-2272 therapy is effective in the setting of chronic PH is unknown. We hypothesize that BAY 41-2272 would prevent PH induced by chronic exposure to neonatal hypoxia. At 2 days of age, newborn rats were randomly exposed to hypoxia (FiO2, 0.12) or room air, and received daily intramuscular treatment with BAY 41-2272 (1 mg/kg) or saline. After 2 weeks, rats were killed for assessment of right ventricular hypertrophy (RVH), wall thickness of small pulmonary arteries, vessels density, radial alveolar counts and mean linear intercepts. In comparison with control, hypoxia increased RVH and artery wall thickness, reduced vessels density, decreased radial alveolar counts and increased mean linear intercepts. In comparison with hypoxic controls, prolonged BAY 41-2272 treatment during chronic hypoxia reduced RVH (0.67 ± 0.03 vs. 0.52 ± 0.05; p < 0.05), and attenuated artery wall thickness (48.2 ± 2.8% vs. 35.7 ± 4.1 µm; p < 0.01). However, BAY 41-2272 did not change vessels density, radial alveolar counts or mean linear intercepts. We conclude that BAY 41-2272 prevents the vascular structural effects of PH and reduces RVH but does not protect from hypoxia-induced inhibition of alveolarization and vessel growth. We speculate that BAY 41-2272 may provide a new therapy for chronic PH.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Levin DL, Heymann MA, Kitterman JA, Gregory GA, Phibbs RH, Rudolph AM: Persistent pulmonary hypertension of the newborn infant. J Pediatr 1976;89:626–630.
  2. Belik J, Keeley FW, Baldwin F, Rabinovitch M: Pulmonary hypertension and vascular remodeling in fetal sheep. Am J Physiol 1994;266:H2303–H2309.
  3. Massaro GD, Olivier J, Massaro D: Short-term perinatal 10% O2 alters postnatal development of lung alveoli. Am J Physiol 1989;257:L221–L225.
  4. Tang JR, Le Cras TD, Morris KG Jr, Abman SH: Brief perinatal hypoxia increases severity of pulmonary hypertension after reexposure to hypoxia in infant rats. Am J Physiol Lung Cell Mol Physiol 2000;278:L356–L364.
  5. Balasubramaniam V, Tang JR, Maxey A, Plopper CG, Abman SH: Mild hypoxia impairs alveolarization in the endothelial nitric oxide synthase-deficient mouse. Am J Physiol Lung Cell Mol Physiol 2003;284:L964–L971.
  6. Young SL, Evans K, Eu JP: Nitric oxide modulates branching morphogenesis in fetal rat lung explants. Am J Physiol Lung Cell Mol Physiol 2002;282:L379–L385.
  7. Chicoine LG, Avitia JW, Deen C, Nelin LD, Earley S, Walker BR: Developmental differences in pulmonary eNOS expression in response to chronic hypoxia in the rat. J Appl Physiol 2002;93:311–318.
  8. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, et al: NO-independent regulatory site on soluble guanylate cyclase. Nature 2001;410:212–215.
  9. Deruelle P, Grover TR, Storme L, Abman SH: Effects of Bay 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 2005;288:L727–L733.

    External Resources

  10. Evgenov OV, Ichinose F, Evgenov NV, Gnoth MJ, Falkowski GE, Chang Y, et al: Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 2004;110:2253–2259.
  11. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Tsuruda T, Harty GJ, Lapp H, et al: Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation 2003;107:686–689.
  12. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, et al: NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 2002;136:773–783.
  13. Deruelle P, Grover TR, Abman SH: Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. Am J Physiol Lung Cell Mol Physiol 2005;289:L798–L806.

    External Resources

  14. Bachofen H, Wangensteen D, Weibel ER: Surfaces and volumes of alveolar tissue under zone II and zone III conditions. J Appl Physiol 1982;53:879–885.
  15. Hayatdavoudi G, Crapo JD, Miller FJ, O’Neil JJ: Factors determining degree of inflation in intratracheally fixed rat lungs. J Appl Physiol 1980;48:389–393.
  16. Fulton RM, Hutchinson EC, Jones AM: Ventricular weight in cardiac hypertrophy. Br Heart J 1952;14:413–420.
  17. Cooney TP, Thurlbeck WM: The radial alveolar count method of Emery and Mithal: a reappraisal 2 – intrauterine and early postnatal lung growth. Thorax 1982;37:580–583.
  18. Cooney TP, Thurlbeck WM: The radial alveolar count method of Emery and Mithal: a reappraisal 1 – postnatal lung growth. Thorax 1982;37:572–579.
  19. Thurlbeck WM: Postnatal human lung growth. Thorax 1982;37:564–571.
  20. Abman SH, Shanley PF, Accurso FJ: Failure of postnatal adaptation of the pulmonary circulation after chronic intrauterine pulmonary hypertension in fetal lambs. J Clin Invest 1989;83:1849–1858.
  21. Blanco LN, Massaro D, Massaro GD: Alveolar size, number, and surface area: developmentally dependent response to 13% O2. Am J Physiol 1991;261:L370–L377.
  22. Keith IM, Tjen ALS, Kraiczi H, Ekman R: Three-week neonatal hypoxia reduces blood CGRP and causes persistent pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol 2000;279:H1571–H1578.
  23. Hakim TS, Mortola JP: Pulmonary vascular resistance in adult rats exposed to hypoxia in the neonatal period. Can J Physiol Pharmacol 1990;68:419–424.
  24. Tang JR, Markham NE, Lin YJ, McMurtry IF, Maxey A, Kinsella JP, et al: Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol 2004;287:L344–L351.

    External Resources

  25. Friebe A, Koesling D: Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 2003;93:96–105.
  26. Roberts JD Jr, Roberts CT, Jones RC, Zapol WM, Bloch KD: Continuous nitric oxide inhalation reduces pulmonary arterial structural changes, right ventricular hypertrophy, and growth retardation in the hypoxic newborn rat. Circ Res 1995;76:215–222.
  27. Hanasato N, Oka M, Muramatsu M, Nishino M, Adachi H, Fukuchi Y: E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats. Am J Physiol 1999;277:L225–L232.
  28. Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, et al: Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001;104:424–428.
  29. Dzau VJ, Gibbons GH: Vascular remodeling: mechanisms and implications. J Cardiovasc Pharmacol 1993;21(suppl 1):S1–S5.

    External Resources

  30. Garg UC, Hassid A: Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774–1777.
  31. Hayden MA, Lange PA, Nakayama DK: Nitric oxide and cyclic guanosine monophosphate stimulate apoptosis via activation of the Fas-FasL pathway. J Surg Res 2001;101:183–189.
  32. Mullershausen F, Russwurm M, Friebe A, Koesling D: Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272. Circulation 2004;109:1711–1713.
  33. Baldwin HS: Early embryonic vascular development. Cardiovasc Res 1996;31:E34–E45.
  34. Gebb SA, Shannon JM: Tissue interactions mediate early events in pulmonary vasculogenesis. Dev Dyn 2000;217:159–169.
  35. Jakkula M, Le Cras TD, Gebb S, Hirth KP, Tuder RM, Voelkel NF, et al: Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol 2000;279:L600–L607.
  36. Fike CD, Kaplowitz MR, Thomas CJ, Nelin LD: Chronic hypoxia decreases nitric oxide production and endothelial nitric oxide synthase in newborn pig lungs. Am J Physiol 1998;274:L517–L526.
  37. Heyes MP, Farber MO, Manfredi F, Robertshaw D, Weinberger M, Fineberg N, et al: Acute effects of hypoxia on renal and endocrine function in normal humans. Am J Physiol 1982;243:R265–R270.
  38. Robinson JS, Jones CT, Thorburn GD: The effects of hypoxaemia in fetal sheep. J Clin Pathol Suppl (R Coll Pathol) 1977;11:127–133.
  39. Tschanz SA, Damke BM, Burri PH: Influence of postnatally administered glucocorticoids on rat lung growth. Biol Neonate 1995;68:229–245.
  40. Kalenga M, Tschanz SA, Burri PH: Protein deficiency and the growing rat lung. II. Morphometric analysis and morphology. Pediatr Res 1995;37:789–795.
  41. Kalenga M, Tschanz SA, Burri PH: Protein deficiency and the growing rat lung. I. Nutritional findings and related lung volumes. Pediatr Res 1995;37:783–788.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50